<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar disorder in pregnant women: Treatment of major depression
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar disorder in pregnant women: Treatment of major depression
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar disorder in pregnant women: Treatment of major depression
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Victoria Hendrick, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H226768143">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications are commonly used to treat pregnant patients, including those with bipolar major depression [
         <a href="#rid1">
          1
         </a>
         ]. At least one prescription drug is taken by more than 60 percent of pregnant patients [
         <a href="#rid2">
          2
         </a>
         ], and psychotropic drugs are taken by 21 to 33 percent [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         This topic discusses treatment of pregnant patients with bipolar major depression. Treatment of manic and hypomanic episodes during pregnancy, prenatal maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal risks of pharmacotherapy for bipolar disorder, and the general treatment of bipolar major depression are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">
          "Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H226768150">
         <span class="h1">
          DEFINITION OF BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6762982">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy is indicated for pregnant patients with bipolar major depression that is characterized by [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicidal or homicidal ideation or behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic features (delusions or hallucinations)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor judgement that places the patient or others at imminent risk of being harmed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe impairment of social or occupational functioning
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H102296868">
         <span class="h1">
          GENERAL PRINCIPLES AND MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar mood episodes during pregnancy are usually treated by perinatal or general psychiatrists in collaboration with obstetricians and primary care clinicians [
         <a href="#rid4">
          4,7-10
         </a>
         ].
        </p>
        <p>
         For pregnant patients with bipolar major depression, treatment is based upon randomized trials that excluded pregnant patients [
         <a href="#rid11">
          11-14
         </a>
         ], as well as observational studies, birth registries, and clinical experience [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Additional information about the general principles and management of treating bipolar mood episodes during pregnancy are discussed separately, as is the general treatment of bipolar major depression. (See
         <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">
          "Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H255235">
         <span class="h2">
          Duration of individual drug trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest treating pregnant patients with bipolar major depression for six to eight weeks before determining whether a specific drug is beneficial, based upon the duration of most randomized trials (which excluded pregnant patients) [
         <a href="#rid11">
          11-13,16
         </a>
         ]. Response is defined as stabilizing the patient’s safety and substantial improvement in the number, intensity, and frequency of symptoms.
        </p>
        <p class="headingAnchor" id="H226769424">
         <span class="h1">
          SELECTING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar major depression during pregnancy is typically treated with pharmacotherapy because it is easier to administer, more widely available, and more acceptable to patients than electroconvulsive therapy (ECT). However, refractory patients may benefit from ECT.
        </p>
        <p class="headingAnchor" id="H140365932">
         <span class="h2">
          First line treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with bipolar major depression, we suggest
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         as first line treatment, based upon efficacy in a meta-analysis of randomized trials that excluded pregnant patients [
         <a href="#rid14">
          14
         </a>
         ]. Up to 40 to 50 percent of patients may respond (defined as stabilizing the patient’s safety and substantial improvement in the number, intensity, and frequency of symptoms). In addition, the reproductive safety profile of lamotrigine is generally regarded as favorable [
         <a href="#rid4">
          4,17,18
         </a>
         ]. The efficacy of lamotrigine and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         appear to be comparable, but there is more experience using lamotrigine during pregnancy than quetiapine. In addition, there is more evidence supporting the efficacy of lamotrigine compared with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         or lamotrigine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and prenatal treatment with monotherapy is preferable to treatment with drug combinations due to concerns about teratogenic effects.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and lamotrigine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ; reproductive safety profile of these drugs; and the dose schedule, side effects  (
         <a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">
          table 5
         </a>
         ) (including life-threatening skin rash), and pharmacology of lamotrigine are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H140365939">
         <span class="h2">
          Treatment resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with bipolar major depression who do not respond to
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         or cannot tolerate it, we suggest
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ], based upon randomized trials that excluded pregnant patients [
         <a href="#rid20">
          20-23
         </a>
         ]. Up to 50 to 60 percent of patients may respond (defined as stabilizing the patient’s safety and substantial improvement in the number, intensity, and frequency of symptoms). In addition, other studies suggest that quetiapine is not associated with teratogenic effects [
         <a href="#rid24">
          24
         </a>
         ], and use of quetiapine for bipolar major depression during pregnancy is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [
         <a href="#rid25">
          25,26
         </a>
         ]. There is more evidence supporting the efficacy of lamotrigine compared with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         or lamotrigine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and prenatal treatment with monotherapy is preferable to treatment with drug combinations due to concerns about teratogenic effects.
        </p>
        <p>
         We generally taper and discontinue
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         at the same time that
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         is started and titrated up. Lamotrigine is usually tapered by the same amount for each dose decrease over a one to two week period. As an example, lamotrigine 200 mg per day is decreased by 50 mg per day every three to four days.
        </p>
        <p>
         Second-generation antipsychotics may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [
         <a href="#rid27">
          27,28
         </a>
         ]. These risks are discussed separately, as are monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics and the efficacy, dose, reproductive safety, pharmacology, and side effects of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Metabolic complications'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Second-generation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H140365946">
         <span class="h2">
          Refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant patients with bipolar major depression often do not respond to sequential trials of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         . For these refractory patients, we suggest tapering and discontinuing quetiapine over one to two weeks at the same time that another medication regimen is started and titrated up. (Response is defined as stabilizing the safety of the patient and others, as well as substantial improvement in the number, intensity, and frequency of symptoms.) Quetiapine is generally tapered by the same amount for each dose decrease. As an example, quetiapine 600 mg per day is decreased by 50 to 100 mg per day, every one to two days.
        </p>
        <p>
         We suggest using the following treatments in sequence for pregnant patients with refractory bipolar major depression, based upon their efficacy in randomized trials (which excluded pregnant patients), reproductive safety profiles, and adverse effects. Although the benefit of
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and the combination of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         appear to be comparable, neither fluoxetine nor olanzapine appear to be associated with teratogenic effects. By contrast, lithium is generally regarded as teratogenic [
         <a href="#rid29">
          29-31
         </a>
         ]. The proportion of patients who respond to any of the following treatment regimens may be as high as approximately 50 percent, based upon trials in nonpregnant patients [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoxetine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          olanzapine
         </strong>
         –
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          Fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         is efficacious for bipolar major depression in nonpregnant patients [
         <a href="#rid12">
          12,32
         </a>
         ]. However, second-generation antipsychotics, especially olanzapine, may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [
         <a href="#rid27">
          27,28
         </a>
         ]. These risks are discussed separately, as are monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics and the efficacy, dose, reproductive safety, pharmacology, and side effects of fluoxetine and olanzapine.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Metabolic complications'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         may need to be increased during pregnancy, especially after 20 weeks gestation, because the volume of distribution (eg, plasma volume) increases during pregnancy, and the activity of hepatic enzymes that metabolize the drug may also increase during pregnancy [
         <a href="#rid33">
          33
         </a>
         ]. However, pharmacokinetic changes during pregnancy vary widely among patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         dose that is prescribed during the third trimester is typically maintained at the end of pregnancy and immediately following delivery [
         <a href="#rid33">
          33
         </a>
         ]. There are no data that support tapering and discontinuing fluoxetine during the third trimester in an effort to avoid neonatal symptoms. However, following delivery, if adverse effects occur in the mother, the dose should be decreased.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lamotrigine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          lithium
         </strong>
         <strong>
         </strong>
         – For pregnant patients with bipolar major depression who do not respond to or tolerate
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , we suggest
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ]. Fluoxetine plus olanzapine are usually tapered and discontinued concurrently over a period of one week, and subsequently lamotrigine and lithium are started and titrated up. Fluoxetine is generally tapered by the same amount for each dose decrease, as is olanzapine. As an example, fluoxetine 40 mg per day is decreased by 10 mg per day every two days, and olanzapine 15 mg per day is decreased by 5 mg per day every three days. Use of lithium in pregnant patients with bipolar disorder who do not respond to antipsychotics is consistent with practice guidelines from the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein anomaly) [
         <a href="#rid29">
          29-31
         </a>
         ], many authorities consider the absolute risk small [
         <a href="#rid1">
          1,4,18,35,36
         </a>
         ]. The reproductive safety profile of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         is generally regarded as favorable [
         <a href="#rid4">
          4,17,18
         </a>
         ], based primarily upon studies of patients with epilepsy. (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose schedule, side effects  (
         <a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">
          table 5
         </a>
         ) (including life-threatening skin rash), and pharmacology of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         are discussed separately; as are the use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         during pregnancy, dose, use of serum concentrations to establish the proper dose, side effects, and pharmacology of lithium.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific medication interactions that can occur may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electroconvulsive therapy (ECT)
         </strong>
         – For refractory pregnant patients with bipolar major depression that does not respond to sequential trials of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and lamotrigine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , we suggest electroconvulsive therapy (ECT). Lamotrigine and lithium are tapered and discontinued over a period of one to two weeks prior to starting ECT. Lamotrigine is generally tapered by the same amount for each dose decrease, as is lithium. As an example, lamotrigine 200 mg per day is decreased by 50 mg per day every three to four days, and lithium 1200 mg per day is tapered by 300 mg per day every three to four days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reviews have found that ECT is efficacious and safe for patients with bipolar major depression who are not pregnant, as well as patients who are pregnant [
         <a href="#rid37">
          37,38
         </a>
         ]; ECT is thus recommended by several practice guidelines [
         <a href="#rid7">
          7,34,39,40
         </a>
         ]. The efficacy, adverse maternal and fetal effects, and reproductive safety of ECT are discussed separately, as is the technique for performing ECT during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">
          "Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Bipolar major depression'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">
          "Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Electroconvulsive therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H256399">
         <span class="h1">
          ADJUNCTIVE TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H181132977">
         <span class="h2">
          Psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with bipolar major depression who are treated with pharmacotherapy, we suggest adjunctive psychotherapy based upon randomized trials in nonpregnant patients [
         <a href="#rid2">
          2,6,41
         </a>
         ]. As an example, a one-year randomized trial compared intensive psychotherapy plus pharmacotherapy with brief psychoeducation plus pharmacotherapy in 293 nonpregnant patients with bipolar major depression [
         <a href="#rid42">
          42
         </a>
         ]. Intensive psychotherapy consisted of family therapy, cognitive-behavioral therapy, or interpersonal and social rhythm therapy, with up to 30 sessions (50 minutes each) administered over nine months; brief psychoeducation included three 50-minute sessions instructing patients about the clinical features and treatment of bipolar disorder. Recovery occurred in more patients who received adjunctive intensive psychotherapy compared with brief psychoeducation (64 versus 52 percent), and outcome did not differ significantly among the three intensive therapies. Using psychotherapy is also supported by randomized trials in pregnant patients with unipolar major depression [
         <a href="#rid43">
          43
         </a>
         ], and is consistent with treatment guidelines [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H256442">
         <span class="h2">
          Omega-3 fatty acids
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with bipolar major depression, dietary supplementation with omega-3 fatty acids (eg, eicosapentaenoic acid 1 to 2 grams per day) as adjunctive treatment is reasonable, based upon limited evidence in meta-analyses of randomized trials (which excluded pregnant patients) and the apparent lack of serious side effects. In addition, prenatal intake of omega-3 fatty acid supplements may have modest beneficial effects on fetal neurodevelopment, and do not have known harmful effects. The efficacy of omega-3 fatty acids for bipolar depression and the risks and benefits during pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/115481.html" rel="external">
          "Bipolar major depression in adults: Investigational and nonstandard approaches to treatment", section on 'Omega-3 fatty acids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17026212">
         <span class="h1">
          RESIDUAL INSOMNIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar major depression in pregnant patients often includes insomnia, which may persist despite resolution of the depressive syndrome. For patients with residual insomnia, we suggest behavioral therapy, including education about sleep hygiene  (
         <a class="graphic graphic_table graphicRef71116" href="/z/d/graphic/71116.html" rel="external">
          table 6
         </a>
         ) and stimulus control  (
         <a class="graphic graphic_table graphicRef77189" href="/z/d/graphic/77189.html" rel="external">
          table 7
         </a>
         ). Patients unresponsive to behavior therapy typically receive additional treatment with low dose
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         . Treatment of insomnia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">
          "Overview of the treatment of insomnia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3813888215">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13497598">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">
          "Patient education: Bipolar disorder (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (See
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These educational materials can be used as part of psychoeducational psychotherapy. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'
         </a>
         .)
        </p>
        <p>
         The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=82788" target="_blank">
          website
         </a>
         or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.
        </p>
        <p>
         More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).
        </p>
        <p>
         The Depression and Bipolar Support Alliance (available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=82788" target="_blank">
          website
         </a>
         or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=82788" target="_blank">
          website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.
        </p>
        <p class="headingAnchor" id="H256488">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Definition of bipolar disorder'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacotherapy is indicated for pregnant patients with bipolar major depression that is characterized by (see
         <a class="local">
          'Indications'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suicidal or homicidal ideation or behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aggressive behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychotic features (delusions or hallucinations)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Poor judgement that places the patient or others at imminent risk of being harmed
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate to severe impairment of social or occupational functioning
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An individual drug trial for pregnant patients with bipolar major depression typically lasts six to eight weeks before determining whether treatment is beneficial. (See
         <a class="local">
          'General principles and management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant patients with bipolar major depression, we suggest
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         as first line treatment rather than other medications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'First line treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant patients with bipolar major depression who do not respond to
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         or cannot tolerate it, we suggest
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         rather than other medications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant patients with refractory bipolar major depression that does not respond to
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         or
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         are often treated with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , lamotrigine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , or electroconvulsive therapy. (See
         <a class="local">
          'Refractory patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant patients with bipolar major depression who are treated with pharmacotherapy, we suggest adjunctive psychotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Psychotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.
          </a>
         </li>
         <li class="breakAll">
          Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.
         </li>
         <li class="breakAll">
          Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N. Mood disorder in the perinatal period. BMJ 2012; 344:e1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194:4.
          </a>
         </li>
         <li class="breakAll">
          Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.463.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marangell LB. Current issues: women and bipolar disorder. Dialogues Clin Neurosci 2008; 10:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma V. Management of bipolar II disorder during pregnancy and the postpartum period--Motherisk Update 2008. Can J Clin Pharmacol 2009; 16:e33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38, 2006. http://www.nice.org.uk/ (Accessed on March 07, 2012).
         </li>
         <li class="breakAll">
          National Institute for Health and Clinical Excellence. NICE clinical guideline 45. Antenatal and postnatal mental health: Clinical management and service guidance. April 2007 http://www.nice.org.uk/CG045 (Accessed on January 01, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol 2014; 34:244.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on August 27, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord 2012; 14:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160:555.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 82788 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422871" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928351" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bipolar disorder and childbirth: the importance of recognising risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22381523" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mood disorder in the perinatal period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19200421" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14609883" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18452345" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118318" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118318" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816033" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18689292" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Current issues: women and bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088587" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Drug treatment for mood disorders in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19164845" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of bipolar II disorder during pregnancy and the postpartum period--Motherisk Update 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20122369" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20122366" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994719" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110817" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22009159" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316639" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425293" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113298" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16889444" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24525634" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24525634" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085677" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Managing bipolar disorder during pregnancy: weighing the risks and benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085677" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Managing bipolar disorder during pregnancy: weighing the risks and benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085677" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Managing bipolar disorder during pregnancy: weighing the risks and benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23237061" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22420597" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404119" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12611838" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
